Biotech startup immunitoAI raises USD1 Million in seed round led by pi Ventures
immunitoAI, a Bangalore based biotech startup that is developing an AI-powered antibody discovery and screening platform, has raised $1 million on Wednesday. The seed round was led by Pi Ventures and Entrepreneur First also participated in the round.
The funds raised by the startup will be utilised for product development and industry partnerships.
“Our focus at pi has been to invest in startups that are revolutionizing industries using disruptive technology. This thesis is well reflected in immunitoAI, our first investment from our recently launched Fund II. The company’s AI-led platform will make the antibody discovery process faster and cheaper, enabling targeted therapy for multiple diseases. We are delighted to partner with Aridni and Trisha, who bring a unique combination of biotech and AI to the table,” said Roopan Aulakh, Managing Director, pi Ventures.
“Integration of AI with biology has become a reality today. Biology has always been difficult to study and understand, but with the use of AI, we have started to bridge the gaps and what was thought to be impossible earlier has become possible. Our vision is to make antibody therapy a norm with the help of our technology. We plan on using this seed funding to develop our AI products and validate the predictions through biological experiments,” said Aridni Shah, CEO and Co-founder, immunitoAI.
Aridni Shah and Trisha Chatterjee founded immunitoAI in Bangalore in November 2020. The startup designs and screens antibody candidates for a given antigen. It is an in-silico antibody discovery startup that uses artificial intelligence to give fast and accurate solutions. Aridni is a PhD in Biological Sciences with 9 years of experience in immunoassays, molecular techniques and data analytics. Whereas Trisha holds a master degree in Computer Science and has 6 years of R&D experience applying artificial intelligence and machine learning in various industries.
immunitoAI aims to increase the number of antibodies discovered drastically, making targeted therapy a norm in future. The startup also plans to develop its own antibody candidates in the mid and long term.
The funds raised by the startup will be utilised for product development and industry partnerships.
“Our focus at pi has been to invest in startups that are revolutionizing industries using disruptive technology. This thesis is well reflected in immunitoAI, our first investment from our recently launched Fund II. The company’s AI-led platform will make the antibody discovery process faster and cheaper, enabling targeted therapy for multiple diseases. We are delighted to partner with Aridni and Trisha, who bring a unique combination of biotech and AI to the table,” said Roopan Aulakh, Managing Director, pi Ventures.
“Integration of AI with biology has become a reality today. Biology has always been difficult to study and understand, but with the use of AI, we have started to bridge the gaps and what was thought to be impossible earlier has become possible. Our vision is to make antibody therapy a norm with the help of our technology. We plan on using this seed funding to develop our AI products and validate the predictions through biological experiments,” said Aridni Shah, CEO and Co-founder, immunitoAI.
Aridni Shah and Trisha Chatterjee founded immunitoAI in Bangalore in November 2020. The startup designs and screens antibody candidates for a given antigen. It is an in-silico antibody discovery startup that uses artificial intelligence to give fast and accurate solutions. Aridni is a PhD in Biological Sciences with 9 years of experience in immunoassays, molecular techniques and data analytics. Whereas Trisha holds a master degree in Computer Science and has 6 years of R&D experience applying artificial intelligence and machine learning in various industries.
immunitoAI aims to increase the number of antibodies discovered drastically, making targeted therapy a norm in future. The startup also plans to develop its own antibody candidates in the mid and long term.
.jpg "Sow & Reap : Empowering Communities through Innovative Bioenergy & Agroforestry Projects")
.jpg "Femtech Startups: On the Cusp of Disruption")
